The Centers for Medicare and Medicaid Services are being urged to make changes that could improve savings for patients and health care payers, as well as expand patient access to biosimilars.
Radioactive iodine treatment for low-risk thyroid cancer is associated with nearly twice the risk of developing acute myeloid leukemia.
A recent study has shown that patients with relapsed or refractory chronic lymphocytic leukemia may prolong their progression-free survival after treatment with a specific combination regimen.
An adjuvant combination regimen may improve the rate of relapse-free survival by 19% in patients with stage III BRAF-mutated melanoma.
Patients with hepatocellular carcinoma who took a reduced therapy dose had a lower cumulative pill cost and were less likely to discontinue treatment due to toxicities.
Following a recent literature review, a team of researchers have proposed new guidelines for the systematic management of side effects associated with CAR-T cell treatment.
A recent study examined whether inpatient palliative care during hematopoietic stem-cell transplant leads to long-term improvements in quality of life and symptom burden for patients.
Previously-treated patients with stage IV NSCLC are less likely to utilize palliative care or hospice services compared with those who receive no prior oncologic treatment.
A patient-driven titration regimen demonstrated better HbA1C control without increasing the risk of hypoglycemia than a physician-driven titration regimen in patients with type 2 diabetes.
The US Food and Drug Administration approved a lower dose of a previously approved therapy for prostate cancer after reviewing a post-marketing study.